S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Biofrontera Stock Forecast, Price & News

-1.11 (-15.63%)
(As of 11/30/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
9.40 million shs
Average Volume
20.92 million shs
Market Capitalization
$69.48 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BFRI News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

About Biofrontera

Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$69.48 million
Not Optionable

Company Calendar

Fiscal Year End


Overall MarketRank

1.83 out of 5 stars

Medical Sector

784th out of 1,390 stocks

Pharmaceutical Preparations Industry

372nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Biofrontera (NASDAQ:BFRI) Frequently Asked Questions

Is Biofrontera a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Biofrontera stock.
View analyst ratings for Biofrontera
or view top-rated stocks.

What price target have analysts set for BFRI?

1 brokerages have issued 1-year price targets for Biofrontera's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Biofrontera's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 233.9% from the stock's current price.
View analysts' price targets for Biofrontera
or view top-rated stocks among Wall Street analysts.

When did Biofrontera IPO?

(BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO.

What is Biofrontera's stock symbol?

Biofrontera trades on the NASDAQ under the ticker symbol "BFRI."

When does the company's quiet period expire?

Biofrontera's quiet period expires on Wednesday, December 8th. Biofrontera had issued 3,600,000 shares in its public offering on October 29th. The total size of the offering was $18,000,000 based on an initial share price of $5.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Biofrontera?

Shares of BFRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biofrontera's stock price today?

One share of BFRI stock can currently be purchased for approximately $5.99.

How much money does Biofrontera make?

Biofrontera has a market capitalization of $69.48 million.

How many employees does Biofrontera have?

Biofrontera employs 2,021 workers across the globe.

What is Biofrontera's official website?

The official website for Biofrontera is www.biofrontera-us.com.

How can I contact Biofrontera?

The company can be reached via phone at 781-245-1325 or via email at [email protected].

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.